Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukaemia (CLL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting. He considers the clinical value of maintenance therapy with anti-CD20 monoclonal antibodies in CLL and molecularly defined subtypes of CLL.